MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Seres Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$2.42−0.04 (-1.63%)
Close on Oct 19, 2026
- Market cap
- $23.59M
- P/E (TTM)
- –
- Dividend yield
- –
Seres Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Seres Therapeutics | Industry median |
|---|---|---|
| Market Cap | $24.06M | $166.30M |
| Enterprise Value | $8.46M | $88.19M |
| PS Ratio | 12.78 | 3.65 |
| PB Ratio | 0.70 | 2.03 |
| P/TBV Ratio | 0.70 | 2.29 |
Enterprise value
| Measure | Seres Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 4.49 | 2.51 |
Income (trailing twelve months)
| Measure | Seres Therapeutics | Industry median |
|---|---|---|
| Revenue | $1.88M | $58.34M |
| Operating Income | -$84.03M | -$21.40M |
| Net Income | -$22.46M | -$22.46M |
| EBITDA | -$80.59M | -$16.91M |
| EPS (Diluted) | -$2.33 | -$0.83 |
Margins
| Measure | Seres Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -4462.8% | -44.0% |
| Profit Margin | -1192.9% | -40.2% |
| EBITDA Margin | -4279.6% | -30.2% |
| FCF Margin | -2724.1% | -9.27% |
Returns
| Measure | Seres Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -66.6% | -53.2% |
| Return on Assets (ROA) | -18.3% | -40.9% |
| Return on Capital Employed (ROCE) | -103.0% | -38.1% |
Growth
| Measure | Seres Therapeutics | Industry median |
|---|---|---|
| Net Income Growth (YoY) | -126.1% | -35.2% |
| EPS Growth (YoY) | -120.7% | -26.2% |
| Revenue Growth (3Y CAGR) | -52.0% | 2.25% |
| Revenue Growth (5Y CAGR) | -52.7% | 6.48% |
Balance sheet
| Measure | Seres Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $15.59M | $61.43M |
| Net Cash (Debt) | $15.59M | $15.35M |
| Net Cash Per Share | $1.57 | $0.66 |
| Equity (Book Value) | $34.53M | $49.09M |
| Book Value Per Share | $3.47 | $1.37 |
| Tangible Book Value | $34.53M | $23.52M |
| Working Capital | $22.32M | $76.81M |
Financial position
| Measure | Seres Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 2.11 | 3.34 |
| Quick Ratio | 0.79 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Seres Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$51.26M | -$12.35M |
| Capital Expenditures | -$37.00K | -$1.08M |
| Free Cash Flow | -$51.30M | -$20.22M |
| FCF Per Share | -$5.16 | -$0.42 |
Efficiency
| Measure | Seres Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.02 | 0.39 |
| Revenue Per Employee | $28.53K | $404.87K |
| Profits Per Employee | -$340.35K | -$703.34K |
| Employee Count | 66 | 74 |
Dividends and yields
| Measure | Seres Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -93.4% | -23.3% |
| FCF Yield | -213.2% | -8.72% |
Shares
| Measure | Seres Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 9,941,260 | 58,127,000 |
| Shares Change (YoY) | 11.0% | 10.9% |
| Shares Change (QoQ) | 2.45% | 0.54% |
| Float | 9,709,090 | 49,136,700 |
| Shares Held by Insiders | 2.34% | 11.6% |
| Shares Held by Institutions | 22.9% | 59.4% |
Taxes
| Measure | Seres Therapeutics | Industry median |
|---|---|---|
| Income Tax | $0 | $79.87K |
Scores
| Measure | Seres Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -15.84 | -0.22 |
| Piotroski F-Score | 6 | 4 |
Calculated by StockData from Seres Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.